Organon & Co. (OGN) Competitors $14.58 +0.14 (+0.97%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends OGN vs. VTRS, SMMT, GMAB, RDY, SRPT, CTLT, PCVX, QGEN, ITCI, and ROIVShould you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Organon & Co. vs. Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Viatris (NASDAQ:VTRS) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do analysts recommend VTRS or OGN? Viatris presently has a consensus price target of $13.67, indicating a potential upside of 9.16%. Organon & Co. has a consensus price target of $21.33, indicating a potential upside of 46.32%. Given Organon & Co.'s stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has higher valuation and earnings, VTRS or OGN? Organon & Co. has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$15.43B0.97$54.70M-$0.74-16.92Organon & Co.$6.41B0.59$1.02B$5.042.89 Is VTRS or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Viatris' net margin of -5.87%. Organon & Co.'s return on equity of 644.70% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-5.87% 16.46% 7.09% Organon & Co. 20.30%644.70%8.12% Does the MarketBeat Community favor VTRS or OGN? Viatris received 5 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 35.48% of users gave Viatris an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformViatrisOutperform Votes2235.48% Underperform Votes4064.52% Organon & Co.Outperform Votes1734.00% Underperform Votes3366.00% Which has more volatility & risk, VTRS or OGN? Viatris has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Do institutionals & insiders believe in VTRS or OGN? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to VTRS or OGN? In the previous week, Viatris had 1 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Viatris and 4 mentions for Organon & Co.. Viatris' average media sentiment score of 0.93 beat Organon & Co.'s score of 0.42 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is VTRS or OGN a better dividend stock? Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.8%. Organon & Co. pays an annual dividend of $1.12 per share and has a dividend yield of 7.7%. Viatris pays out -64.9% of its earnings in the form of a dividend. Organon & Co. pays out 22.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. SummaryOrganon & Co. beats Viatris on 11 of the 20 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Organon & Co. News Delivered to You Automatically Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGN vs. The Competition Export to ExcelMetricOrganon & Co.Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.75B$6.57B$5.02B$19.19BDividend Yield7.32%3.09%4.87%3.57%P/E Ratio2.8910.55135.2041.24Price / Sales0.59194.011,120.3117.58Price / Cash3.0557.1640.5821.28Price / Book-54.005.104.755.32Net Income$1.02B$151.51M$118.50M$989.67M7 Day Performance-4.64%-2.16%-1.83%-3.59%1 Month Performance-0.98%-2.91%12.27%-2.48%1 Year Performance10.87%13.93%31.72%13.87% Organon & Co. Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGNOrganon & Co.4.794 of 5 stars$14.58+1.0%$21.33+46.3%+10.9%$3.75B$6.41B2.8910,000High Trading VolumeVTRSViatris2.0866 of 5 stars$12.67+0.3%$13.67+7.9%+19.8%$15.12B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.81+5.5%$33.33+77.2%+636.9%$13.87B$700,000.00-63.68105News CoverageGMABGenmab A/S4.1997 of 5 stars$20.13-0.2%$45.20+124.5%-33.5%$13.32B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.76+2.1%$17.00+15.2%+15.8%$12.32B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$125.93+1.8%$178.71+41.9%+31.8%$12.03B$1.64B98.971,314Analyst ForecastPositive NewsCTLTCatalent2.7804 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6118 of 5 stars$90.22+2.8%$147.50+63.5%+45.4%$11.25BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.7279 of 5 stars$45.48+0.2%$51.15+12.5%+3.1%$10.38B$1.97B117.035,967ITCIIntra-Cellular Therapies4.025 of 5 stars$84.49+1.8%$97.23+15.1%+27.8%$8.96B$612.78M-95.91560ROIVRoivant Sciences3.0418 of 5 stars$12.08+2.0%$17.93+48.4%+16.2%$8.79B$129.13M2.10860Insider TradePositive News Related Companies and Tools Related Companies VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives SRPT Alternatives CTLT Alternatives PCVX Alternatives QGEN Alternatives ITCI Alternatives ROIV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:OGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OGN Stock Alerts